XFOR X4 Pharmaceuticals, Inc.
Healthcare$4.01+0.00%OpenMarket Cap: $45.8M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.03
P/S
5.11
EV/EBITDA
1.76
DCF Value
$22.51
FCF Yield
-158.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
79.4%
Operating Margin
-1084.4%
Net Margin
-1106.3%
ROE
-94.9%
ROA
-36.9%
ROIC
-39.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $2.7M | 77.9% | $-20.3M | $-20.2M | $— | — |
| Q4 null | $2.6M | 84.9% | $-23.7M | $-23.9M | $— | — |
| FY null | $35.1M | 82.2% | $-86.9M | $-79.2M | $— | — |
| Q3 null | $1.8M | 78.8% | $-27.5M | $-29.8M | $— | — |
| Q2 null | $2.0M | 75.0% | $-26.2M | $-25.7M | $— | — |
| Q1 null | $28.8M | 82.6% | $-9.4M | $282.0K | $— | — |
| Q4 null | $1.4M | 78.9% | $-35.7M | $-39.8M | $— | — |
| FY null | $2.6M | 68.8% | $-36.4M | $-37.5M | $— | — |
| Q3 null | $560.0K | 45.2% | $-34.5M | $-36.7M | $— | — |
| Q2 null | $563.0K | 17.9% | $-33.9M | $90.8M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-37.3M | $-51.8M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-25.2M | $-19.1M | $-2.89 | — |